NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1

Journal of Endocrinology

Volumn 204, Issue 1, 2010, Pages 47-56

  Li, Qinkai ^a,b,c   Yin, Weidong ^a   Cai, Manbo ^a   Liu, Yi ^a   Hou, Hongjie ^a   Shen, Qingyun ^a   Zhang, Chi ^a   Xiao, Junxia ^a   Hu, Xiaobo ^a   Wu, Qishisan ^b   Funaki, Makoto ^c   Nakaya, Yutaka ^b  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RNA; SOMATOMEDIN C; STAT5 PROTEIN; SUCROSE; 4-DIETHOXYPHOSPHORYLMETHYL-N-(4-BROMO-2-CYANOPHENYL)BENZAMIDE; ANTILIPEMIC AGENT; BENZAMIDE DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CELL CULTURE; CELL STRAIN HEPG2; CHOLESTEROL DIET; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID STORAGE; LONG TERM CARE; MALE; MINIPIG; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; WESTERN BLOTTING; ANIMAL; ANIMAL FOOD; BLOOD; DRUG ADMINISTRATION; FAT INTAKE; HYPERGLYCEMIA; HYPERINSULINISM; LIVER; METABOLISM; SECRETION; SWINE; TUMOR CELL LINE; UPREGULATION;

ANIMAL FEED; ANIMALS; ANTILIPEMIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CHOLESTEROL; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY FATS; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LIVER; MALE; ORGANOPHOSPHORUS COMPOUNDS; STAT5 TRANSCRIPTION FACTOR; SWINE; SWINE, MINIATURE; UP-REGULATION;

EID: 73949096823     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-09-0278     Document Type: Article

References (52)

1. Bellinger DA, Merricks EP & Nichols TC 2006 Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications. ILAR Journal/National Research Council, Institute of Laboratory Animal Resources 47 243-258.
2. Brown MS & Goldstein JL 1986 A receptor-mediated pathway for cholesterol homeostasis. Science 232 34-47.
3. Brownlee M 2005 The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 1615-1625.
4. Chawla A, Saez E & Evans RM 2000 Don't know much bile-ology. Cell 103 1-4.
5. Chia DJ, Ono M, Woelfle J, Schlesinger-Massart M, Jiang H & Rotwein P 2006 Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription. Journal of Biological Chemistry 281 3190-3197.
6. Chiang JY 1998 Regulation of bile acid synthesis. Frontiers in Bioscience 3 d176-d193.
7. Chiang JY, Kimmel R & Stroup D 2001 Regulation of cholesterol 7alphahydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 262 257-265.
8. Clark RG, Thomas GB, Mortensen DL, Won WB, Ma YH, Tomlinson EE, Fairhall KM & Robinson IC 1997 Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. Endocrinology 138 4316-4323.
9. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ & Grattan DR 2001 STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology 142 3836-3841.
10. DeFronzo RA & Ferrannini E 1991 Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 173-194.
11. Eckel RH, Grundy SM & Zimmet PZ 2005 The metabolic syndrome. Lancet 365 1415-1428.
12. Fielding CJ & Fielding PE 1995 Molecular physiology of reverse cholesterol transport. Journal of Lipid Research 36 211-228.
13. Froesch ER, Hussain MA, Schmid C & Zapf J 1996 Insulin-like growth factor I: physiology, metabolic effects and clinical uses. Diabetes/ Metabolism Reviews 12 195-215.
14. Frost RA, Nystrom GJ & Lang CH 2002 Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts. Endocrinology 143 492-503.
15. Goldberg IJ 1996 Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. Journal of Lipid Research 37 693-707.
16. Goodwin B, Watson MA, Kim H, Miao J, Kemper JK & Kliewer SA 2003 Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Molecular Endocrinology 17 386-394.
17. Horton JD, Cuthbert JA & Spady DK 1995 Regulation of hepatic 7 alphahydroxylase expression and response to dietary cholesterol in the rat and hamster. Journal of Biological Chemistry 270 5381-5387.
18. Javitt NB 1994 Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB Journal 8 1308-1311.
19. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, Limana F, Nadal-Ginard B, Leri A & Anversa P 2001 IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50 1414-1424.
20. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 680-685.
21. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J & Mangelsdorf DJ 2000 Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Molecular Cell 6 507-515.
22. Massa G, Dooms L, Bouillon R & Vanderschueren-Lodeweyckx M 1993 Serum levels of growth hormone-binding protein and insulin-like growth factor I in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36 239-243.
23. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A et al. 1996 Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379 645-648.
24. Miquet JG, Sotelo AI, Bartke A & Turyn D 2004 Suppression of growth hormone (GH) Janus tyrosine kinase 2/signal transducer and activator of transcription 5 signaling pathway in transgenic mice overexpressing bovine GH. Endocrinology 145 2824-2832.
25. Moller DE & Flier JS 1991 Insulin resistance - mechanisms, syndromes, and implications. New England Journal of Medicine 325 938-948.
26. Moller DE & Kaufman KD 2005 Metabolic syndrome: a clinical and molecular perspective. Annual Review of Medicine 56 45-62.
27. Myant NB & Mitropoulos KA 1977 Cholesterol 7 alpha-hydroxylase. Journal of Lipid Research 18 135-153.
28. Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T &Wakabayashi K 2005 Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. PNAS 102 2970-2974.
29. Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, Miyajima A & Kitamura T 1998 Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Molecular and Cellular Biology 18 3871-3879.
30. Osada R, Ohshima H, Ishihara H, Yudoh K, Sakai K, Matsui H & Tsuji H 1996 Autocrine/paracrine mechanism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs. Journal of Orthopaedic Research 14 690-699.
31. Pandak WM, Stravitz RT, Lucas V, Heuman DM & Chiang JY 1996 Hep G2 cells: a model for studies on regulation of human cholesterol 7alphahydroxylase at the molecular level. American Journal of Physiology 270 G401-G410.
32. Pandak WM, Schwarz C, Hylemon PB,Mallonee D, Valerie K, Heuman DM, Fisher RA, Redford K & Vlahcevic ZR 2001 Effects of CYP7A1 overexpression on cholesterol and bile acid homeostasis. American Journal of Physiology. Gastrointestinal and Liver Physiology 281 G878-G889.
33. Patel DD, Knight BL, Soutar AK, Gibbons GF & Wade DP 2000 The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. Biochemical Journal 351 747-753.
34. Ratliff EP, Gutierrez A & Davis RA 2006 Transgenic expression of CYP7A1 in LDL receptor-deficient mice blocks diet-induced hypercholesterolemia. Journal of Lipid Research 47 1513-1520.
35. Repa JJ & Mangelsdorf DJ 2000 The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annual Review of Cell and Developmental Biology 16 459-481.
36. Spady DK, Cuthbert JA, Willard MN & Meidell RS 1995 Adenovirusmediated transfer of a gene encoding cholesterol 7 alpha-hydroxylase into hamsters increases hepatic enzyme activity and reduces plasma total and low density lipoprotein cholesterol. Journal of Clinical Investigation 96 700-709.
37. Takano A, Usui I, Haruta T, Kawahara J, Uno T, Iwata M & Kobayashi M 2001 Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Molecular and Cellular Biology 21 5050-5062.
38. Trigatti B, Rigotti A & Krieger M 2000 The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Current Opinion in Lipidology 11 123-131.
39. Tsutsumi K, Inoue Y, Shima A, Iwasaki K, Kawamura M & Murase T 1993 The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. Journal of Clinical Investigation 92 411-417.
40. Tsutsumi K, Inoue Y, Hagi A & Murase T 1997 The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity. Metabolism 46 257-260.
41. Turley SD & Dietschy JM 1988 The Liver: Biology and Pathobiology, New York: Raven Press.
42. Vidal OM, Merino R, Rico-Bautista E, Fernandez-Perez L, Chia DJ, Woelfle J, Ono M, Lenhard B, Norstedt G, Rotwein P et al. 2007 In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Molecular Endocrinology 21 293-311.
43. Woelfle J & Rotwein P 2004 In vivo regulation of growth hormone-stimulated gene transcription by STAT5b. American Journal of Physiology. Endocrinology and Metabolism 286 E393-E401.
44. Woelfle J, Billiard J & Rotwein P 2003 Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. Journal of Biological Chemistry 278 22696-22702.
45. Xi S, YinW,Wang Z, Kusunoki M, Lian X, Koike T, Fan J & Zhang Q 2004 A minipig model of high-fat/high-sucrose diet-induced diabetes and atherosclerosis. International Journal of Experimental Pathology 85 223-231.
46. Yakar S, Liu JL, Fernandez AM,Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W & Le Roith D 2001 Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 50 1110-1118.
47. Yin W, Yuan Z, Tsutsumi K, Xie Y, Zhang Q, Wang Z, Fu G, Long G & Yang Y 2003 A lipoprotein lipase-promoting agent, NO-1886, improves glucose and lipid metabolism in high fat, high sucrose-fed New Zealand white rabbits. International Journal of Experimental Diabetes Research 4 27-34.
48. Yin W, Liao D, Kusunoki M, Xi S, Tsutsumi K, Wang Z, Lian X, Koike T, Fan J, Yang Y et al. 2004a NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine. Journal of Endocrinology 180 399-408.
49. Yin W, Liao D, Wang Z, Xi S, Tsutsumi K, Koike T, Fan J, Yi G, Zhang Q, Yuan Z et al. 2004b NO-1886 inhibits size of adipocytes, suppresses plasma levels of tumor necrosis factor-alpha and free fatty acids, improves glucose metabolism in high-fat/high-sucrose-fed miniature pigs. Pharmacological Research 49 199-206.
50. Yu J, Chu ES, Hui AY, Cheung KF, Chan HL, Leung WK, Farrell GC & Sung JJ 2007 Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. Biochemical and BiophysicalResearchCommunications 356 53-59.
51. Zhang C, YinW, Liao D, Huang L, Tang C, Tsutsumi K,Wang Z, Liu Y, LiQ, Hou H et al. 2006 NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs. Journal of Lipid Research 47 2055-2063.
52. Zhou YC & Waxman DJ 1999 STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligandindependent activation function region-1 trans-activation domain. Journal of Biological Chemistry 274 29874-29882.